---
schema_version: "secwatch.filing_event.v1"
accession: "0002019410-26-000040"
form_type: "8-K"
ticker: "CAI"
cik: "0002019410"
company_name: "Caris Life Sciences, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:05:53.486641+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caris Life Sciences Q1 revenue up 79% to $216.2M, net loss narrows to $0.5M

## Summary
- Revenue $216.2M (+79% YoY); gross margin 65% vs 47% a year ago.
- Net loss $0.5M vs $102.6M loss in Q1 2025; positive Adj. EBITDA $26.2M.
- Completed ~52,800 clinical cases (+15% YoY); reaffirms FY2026 revenue guidance $1.0-$1.02B.
- Free cash flow positive $22.5M, inclusive of $30.5M annual bonus payments.
- Launched MolDX-approved Caris ChromoSeq; refinanced $400M credit facility with Blue Owl/Blackstone.

## SEC filing metadata
- accession: 0002019410-26-000040
- form_type: 8-K
- ticker: CAI
- cik: 0002019410
- company_name: Caris Life Sciences, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/cai-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002019410-26-000040
- JSON: https://secwatch.observer/filing/0002019410-26-000040.json
- Plain text: https://secwatch.observer/filing/0002019410-26-000040.txt

## Source-grounded claims
- claim_id: 817f28728e78b072be993fa612f4c5d36d1c235e
  claim: Caris Life Sciences, Inc. reported the quarter ended March 31, 2026 results: revenue Total revenue was $216.2 million, net income Net loss was $0.5 million, EPS Net loss per share attributable to common shareholders, basic and diluted, was $0.00. Guidance reaffirmed.
  evidence_excerpt: Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of
  evidence_url: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.